SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HerbVic who wrote (7105)10/6/2015 2:55:02 AM
From: loparn1 Recommendation

Recommended By
HerbVic

   of 7143
 
Thank you for the input. As I understand it Foxy-5 could be the first administered effective drug overall in directly inhibiting cancer cells from leaving a newly diagnosed primary tumor, travelling to the blodstream and invading another organ and thus substantially reduce the risk for metastasis to develop.

Foxy-5 does this by mimicking the natural protein Wnt-5a which inhibits up to 6 such different (downstream) mechanism in breast cancer. It has been preclinically shown in vitro in detail for breast cancer how this works and there are in vivo studies supporting that the antimetastatic effect occurs and that a high Wnt-5a-expression clinically correlates to a significantly longer diseasefree life.

The downstream antimetastatic mechanisms of Wnt-5a differ to a degree in colon and prostate cancer.

I think the doctors will love this medicine i.e. if WntResearch (and or a future Big Pharma partner) succeeds, and hopefully millions of cancer patients will as well.
The CEO of WntResearch professor Nils Brünner is very optimistic about Foxy-5.
So is the "brain" behind Foxy-5 the WntResearch CSO professor Tommy Andersson.

But there is of course always a risk in drug development...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News